MiCAN Technologies Inc. (Head office: Kyoto, Japan; Representative Director: Kazuo Miyazaki) has issued new shares for a total of 200 million yen through a third-party allotment to Realtech Fund III Investment Limited Partnership (unlimited liability partner: Realtech Japan, LLC (Minato-ku, Tokyo; Representative Executive Officer: Akihiko Nagata)), Shimadzu Diagnostics Corp. (Head office: Taito-ku, Tokyo; Representative Executive Officer: Tokuya Ono), and Fujimori Kogyo Corp. (Head office: Bunkyo-ku, Tokyo; Representative Director: Eishi Fuyama).
We will use the funds raised this time to prepare a stable supply system, distribution and sales system of MylcMAT together with the operating companies, and aim to start supplying the product as soon as possible. We will also support the development of drugs and vaccines by providing MylcMAT, which utilizes the microenvironmental characteristics of monocytes, as we have cultivated the technique in our research on immortalized myeloid cells (Mylc cells) and viral infections.
